Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets recover
Thu, 6 Jun 01:30 pm

Indian share markets recovered lost ground in the post-noon trading session, but continued to trade slightly below the dotted line. Majority of the sectoral indices are trading in the red with pharma, metal and oil & gas stocks being the biggest losers. Capital goods, realty and banking stocks are among the few stocks trading positive.

BSE-Sensex is down 15 points and NSE-Nifty is trading 2 points down. Both BSE Mid Cap and BSE Small Cap indices are trading marginally up. The rupee is trading at 56.8 to the US dollar.

Domestic pharma stocks Indian Pharma - Live Stock Quotes and Analysis Update from Equitymaster.com are trading mixed with, Elder pharma and Cipla Ltd leading among gainers while Glenmark Pharma and Ranbaxy Laboratories are the major losers. As per a leading financial daily, the South African drug regulator body has said that the drugs supplied by Ranbaxy in the country are safe and efficacious. Mandisa Hela who is registrar of South African Medicines Control Council (MCC) gave this statement. Reportedly, Hela also mentioned that regulators from other countries such as from Australia, UK have also visited the facility and were satisfied with the standards. The South African subsidiary of Ranbaxy has also issued similar statement, assuring that even the drugs which are manufactured locally were safe.

As per a leading financial daily, the government has raised the customs duty on gold by 2% to 8%. This is the second increase in six months to curb rising gold imports and thereby put a check on the widening current account deficit. While the import duty on gold bars, coins and platinum has been increased from 6% to 8%, the custom duty on gold ores and concentrates that are used in the manufacture of gold has been raised to 6%. This move is expected to raise the raw material costs for jewellery manufacturers. Gold imports surged by 138% to $ 7.5 bn in April 2013. As per the World Gold Council, gold consumption is expected to rise to 865-960 tons in 2013 from 864 tons in 2012.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets recover". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.